目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 48)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 AUTOINJECTORS MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 54)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES
FIGURE 4 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES
FIGURE 5 MARKET SIZE ESTIMATION: OVERALL APPROACH
FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: APPROACH 1 (REVENUE SHARE ANALYSIS)
2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS
FIGURE 7 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
FIGURE 8 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: APPROACH 1 (REVENUE SHARE ANALYSIS)
2.3.1 INSIGHTS FROM PRIMARIES
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 GROWTH FORECAST
FIGURE 11 MARKET: CAGR PROJECTIONS
FIGURE 12 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS
FIGURE 13 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 14 DATA TRIANGULATION METHODOLOGY
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ANALYSIS
2.8 IMPACT OF RECESSION ON MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY (Page No. - 68)
FIGURE 15 AUTOINJECTORS MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION)
FIGURE 16 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2023 VS. 2028 (USD BILLION)
FIGURE 17 MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
FIGURE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
FIGURE 19 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 20 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 21 GEOGRAPHICAL SNAPSHOT: MARKET
FIGURE 22 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR FINISHED FORMULATIONS MARKET

4 PREMIUM INSIGHTS (Page No. - 74)
4.1 AUTOINJECTOR FINISHED FORMULATIONS AND DEVICES MARKET OVERVIEW
FIGURE 23 INCREASING NUMBER OF REGULATORY APPROVALS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: AUTOINJECTORS MARKET SHARE, BY USAGE AND COUNTRY (2022)
FIGURE 24 DISPOSABLE AUTOINJECTORS SEGMENT DOMINATED NORTH AMERICAN MARKET IN 2022
4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND COUNTRY (2022)
FIGURE 25 SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR FINISHED FORMULATIONS MARKET IN 2022
4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2023 VS. 2028 (USD MILLION)
FIGURE 26 RHEUMATOID ARTHRITIS SEGMENT TO CONTINUE TO DOMINATE MARKET BY 2028
4.5 OVERALL MARKET SHARE, BY TECHNOLOGY, 2022
FIGURE 27 MANUAL AUTOINJECTORS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 28 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET FROM 2023 TO 2028
4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR FINISHED FORMULATIONS MARKET FROM 2023 TO 2028

5 MARKET OVERVIEW (Page No. - 79)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 30 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Benefits of autoinjectors in emergency medical care
5.2.1.2 Increasing regulatory approvals for autoinjectors
TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE
5.2.1.3 Availability of generics and biosimilars in autoinjectors
5.2.1.4 Government support and favorable reimbursements
5.2.1.5 Growing awareness and adoption of self-administration
5.2.2 RESTRAINTS
5.2.2.1 Alternative drug delivery modes and needle phobia
5.2.3 OPPORTUNITIES
5.2.3.1 Patent expiry of biologics
TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS
5.2.3.2 Increasing shift of therapy to home settings
5.2.4 CHALLENGES
5.2.4.1 Development of autoinjectors for multiple drug viscosities
5.3 KEY INDUSTRY TRENDS
5.3.1 INCREASING ADOPTION OF WEARABLE AUTOINJECTORS
5.3.2 DEVELOPMENT AND LAUNCH OF ENVIRONMENT-FRIENDLY AUTOINJECTORS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 31 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOINJECTOR PROVIDERS
5.5 PRICING ANALYSIS
TABLE 5 AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 2020
TABLE 6 INDICATIVE PRICING ANALYSIS OF AUTOINJECTOR FINISHED FORMULATIONS
5.6 VALUE CHAIN ANALYSIS
FIGURE 32 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 33 MARKET: SUPPLY CHAIN ANALYSIS
TABLE 7 OVERALL SUPPLY CHAIN ECOSYSTEM FOR AUTOINJECTORS
5.8 ECOSYSTEM ANALYSIS
FIGURE 34 ECOSYSTEM ANALYSIS: MARKET
5.9 TECHNOLOGY ANALYSIS
5.10 PATENT ANALYSIS
FIGURE 35 PATENT APPLICATIONS FOR AUTOINJECTORS, JANUARY 2012-APRIL 2023
TABLE 8 INDICATIVE LIST OF PATENTS IN MARKET
5.11 KEY CONFERENCES AND EVENTS IN 2023-2024
TABLE 9 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.12 TRADE DATA
TABLE 10 IMPORT AND EXPORT DATA FOR PRODUCTS INCLUDING AUTOINJECTORS, AMONG OTHERS, 2022
5.13 REGULATORY ANALYSIS
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTES
5.14.3 BARGAINING POWER OF SUPPLIERS
5.14.4 BARGAINING POWER OF BUYERS
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTOR DEVICES
5.15.2 BUYING CRITERIA FOR AUTOINJECTOR DEVICES
FIGURE 37 KEY BUYING CRITERIA FOR END USERS

6 AUTOINJECTORS MARKET, BY USAGE (Page No. - 103)
6.1 INTRODUCTION
TABLE 16 MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 17 MARKET, BY USAGE, 2021-2028 (MILLION UNITS)
TABLE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
6.2 DISPOSABLE AUTOINJECTORS
6.2.1 CONVENIENCE OF USE FOR PATIENTS TO DRIVE GROWTH
TABLE 19 MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 20 MARKET, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 21 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 22 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 24 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 25 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 26 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
6.3 REUSABLE AUTOINJECTORS
6.3.1 REUSABLE AUTOINJECTORS TO ACCOUNT FOR LOWER SHARE OF MARKET
TABLE 28 MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 29 MARKET, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 30 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 31 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 33 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 34 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 35 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 AUTOINJECTORS MARKET, BY TECHNOLOGY (Page No. - 113)
7.1 INTRODUCTION
TABLE 37 AUTOINJECTORS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 38 MARKET, BY TECHNOLOGY, 2021-2028 (MILLION UNITS)
TABLE 39 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
7.2 MANUAL AUTOINJECTORS
7.2.1 MANUAL AUTOINJECTORS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE DURING FORECAST PERIOD
TABLE 40 MANUAL MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 41 MANUAL MARKET, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 42 NORTH AMERICA: MANUAL MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 43 EUROPE: MANUAL MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC: MANUAL MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 45 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 46 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
7.3 AUTOMATIC AUTOINJECTORS
7.3.1 AUTOMATIC AUTOINJECTORS INTEGRATE ELECTRONIC COMPONENTS AND ADDITIONAL FEATURES TO ENHANCE INJECTION PROCESS
TABLE 49 MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 50 MARKET, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 51 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 52 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 54 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 55 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 56 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 57 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 123)
8.1 INTRODUCTION
TABLE 58 MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 59 MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (MILLION UNITS)
8.2 SUBCUTANEOUS
8.2.1 INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE GROWTH
TABLE 60 MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 61 SUBCUTANEOUS MARKET, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 62 NORTH AMERICA: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 63 EUROPE: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 64 ASIA PACIFIC: MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
8.3 INTRAMUSCULAR
8.3.1 INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES FASTER ABSORPTION OF MEDICATION
TABLE 65 MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
TABLE 66 INTRAMUSCULAR MARKET, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 67 NORTH AMERICA: MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 68 EUROPE: MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 69 ASIA PACIFIC: MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)

9 AUTOINJECTORS MARKET, BY THERAPY AREA (Page No. - 130)
9.1 INTRODUCTION
TABLE 70 MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 71 MARKET, BY THERAPY AREA, 2021-2028 (MILLION UNITS)
TABLE 72 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
9.2 RHEUMATOID ARTHRITIS
9.2.1 BENEFITS OF AUTOINJECTORS IN RHEUMATOID ARTHRITIS TREATMENT TO PROPEL GROWTH
TABLE 73 MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 74 MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 75 NORTH AMERICA: MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 76 EUROPE: MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 78 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 79 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 80 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 81 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
9.3 DIABETES
9.3.1 LARGE DIABETIC POPULATION TO DRIVE DEMAND FOR AUTOINJECTORS
FIGURE 38 DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20-79 YEARS), 2019 VS. 2030 VS. 2045
TABLE 82 MARKET FOR DIABETES, BY REGION, 2021-2028 (USD MILLION)
TABLE 83 MARKET FOR DIABETES, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 84 NORTH AMERICA: MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 85 EUROPE: MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 86 ASIA PACIFIC: MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 87 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2021-2028 (USD MILLION)
TABLE 88 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 89 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
9.4 MULTIPLE SCLEROSIS
9.4.1 AVAILABILITY OF ORAL GENERIC MEDICINES TO NEGATIVELY IMPACT GROWTH
TABLE 91 MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 92 MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 93 NORTH AMERICA: MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 96 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 97 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 98 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 99 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
9.4.2 ANAPHYLAXIS
9.4.2.1 Increasing prevalence of food allergies to drive growth
TABLE 100 MARKET FOR ANAPHYLAXIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 101 MARKET FOR ANAPHYLAXIS, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 102 NORTH AMERICA: MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 103 EUROPE: MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 104 ASIA PACIFIC: MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 105 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2021-2028 (USD MILLION)
TABLE 106 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 107 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 108 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
9.4.3 OTHER THERAPY AREAS
TABLE 109 MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021-2028 (USD MILLION)
TABLE 110 MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021-2028 (MILLION UNITS)
TABLE 111 NORTH AMERICA: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 112 EUROPE: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 113 ASIA PACIFIC: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 114 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021-2028 (USD MILLION)
TABLE 115 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 116 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

10 AUTOINJECTORS MARKET, BY VOLUME (Page No. - 153)
10.1 INTRODUCTION
TABLE 118 MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 119 MARKET, BY VOLUME, 2021-2028 (MILLION UNITS)
10.2 UP TO 3 ML VOLUME
10.2.1 INCREASING USE OF SUBCUTANEOUS INJECTIONS AGAINST CHRONIC DISEASES TO DRIVE GROWTH
TABLE 120 UP TO 3 ML VOLUME MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 121 UP TO 3 ML VOLUME MARKET, BY REGION, 2021-2028 (MILLION UNITS)
10.3 ABOVE 3 ML VOLUME (LARGE VOLUME)
10.3.1 GROWING RESEARCH TO STUDY POTENTIAL OF LARGE-VOLUME AUTOINJECTORS TO DRIVE GROWTH
TABLE 122 ABOVE 3 ML VOLUME MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 123 ABOVE 3 ML VOLUME MARKET, BY REGION, 2021-2028 (MILLION UNITS)

11 AUTOINJECTORS MARKET, BY END USER (Page No. - 157)
11.1 INTRODUCTION
TABLE 124 MARKET, BY END USER, 2021-2028 (USD MILLION)
11.2 HOME CARE SETTINGS
11.2.1 COST-EFFECTIVENESS OF HOME CARE THERAPIES TO PROPEL GROWTH
TABLE 125 MARKET FOR HOME CARE SETTINGS, BY REGION, 2021-2028 (USD MILLION)
TABLE 126 NORTH AMERICA: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 127 EUROPE: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 128 ASIA PACIFIC: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
11.3 HOSPITALS AND CLINICS
11.3.1 USE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS AND CLINICS TO DRIVE GROWTH
TABLE 129 MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION)
TABLE 130 NORTH AMERICA: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 131 EUROPE: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 132 ASIA PACIFIC: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
11.4 AMBULATORY CARE SETTINGS
11.4.1 INCREASING PATIENT VOLUME IN AMBULATORY CARE SETTINGS TO DRIVE GROWTH
TABLE 133 MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2021-2028 (USD MILLION)
TABLE 134 NORTH AMERICA: MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 135 EUROPE: MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 136 ASIA PACIFIC: MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)

12 AUTOINJECTORS MARKET, BY REGION (Page No. - 165)
12.1 INTRODUCTION
TABLE 137 MARKET, BY REGION, 2021-2028 (USD MILLION)
TABLE 138 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
12.2 NORTH AMERICA
FIGURE 39 NORTH AMERICA: AUTOINJECTORS MARKET SNAPSHOT
TABLE 139 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 140 NORTH AMERICA: MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 141 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 142 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 143 NORTH AMERICA: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 144 NORTH AMERICA: MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 145 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 146 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 147 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 148 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 149 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 150 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 151 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 152 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.1 US
12.2.1.1 US to dominate North American market during forecast period
TABLE 153 AUTOINJECTORS APPROVED BY US FDA, 2022
TABLE 154 US: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 155 US: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 156 US: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 157 US: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 158 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 159 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 160 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 161 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 162 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 163 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.2 CANADA
12.2.2.1 Rising prevalence of chronic diseases to drive growth
TABLE 164 CANADA: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 165 CANADA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 166 CANADA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 167 CANADA: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 168 CANADA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 169 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 170 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 171 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 172 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 173 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.2.3 NORTH AMERICA: RECESSION IMPACT
12.3 EUROPE
TABLE 174 EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 175 EUROPE: MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 176 EUROPE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 177 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 178 EUROPE: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 179 EUROPE: MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 180 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 181 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 182 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 183 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 184 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 185 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 186 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 187 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.1 GERMANY
12.3.1.1 Growing government support to propel market
TABLE 188 GERMANY: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 189 GERMANY: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 190 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 191 GERMANY: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 192 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 193 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 194 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 195 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 196 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 197 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.2 UK
12.3.2.1 High prevalence of allergic conditions to boost growth
TABLE 198 UK: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 199 UK: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 200 UK: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 201 UK: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 202 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 203 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 204 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 205 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 206 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 207 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.3 FRANCE
12.3.3.1 Increasing prevalence of chronic diseases to support growth
TABLE 208 FRANCE: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 209 FRANCE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 210 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 211 FRANCE: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 212 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 213 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 214 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 215 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 216 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 217 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.4 ITALY
12.3.4.1 Rising prevalence of chronic diseases to propel growth
TABLE 218 ITALY: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 219 ITALY: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 220 ITALY: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 221 ITALY: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 222 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 223 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 224 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 225 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 226 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 227 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.5 SPAIN
12.3.5.1 Favorable reimbursement scenario to support growth
TABLE 228 SPAIN: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 229 SPAIN: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 230 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 231 SPAIN: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 232 SPAIN: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 233 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 234 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 235 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 236 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 237 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.6 REST OF EUROPE
TABLE 238 REST OF EUROPE: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 239 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 240 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 241 REST OF EUROPE: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 242 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 243 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 244 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 245 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 246 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 247 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.3.7 EUROPE: RECESSION IMPACT
12.4 ASIA PACIFIC
FIGURE 40 ASIA PACIFIC: AUTOINJECTORS MARKET SNAPSHOT
TABLE 248 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 249 ASIA PACIFIC: MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 250 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 251 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 252 ASIA PACIFIC: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 253 ASIA PACIFIC: MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 254 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 255 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 256 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 257 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 258 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 259 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 260 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 261 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.1 JAPAN
12.4.1.1 Presence of large geriatric population to boost growth
TABLE 262 JAPAN: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 263 JAPAN: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 264 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 265 JAPAN: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 266 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 267 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 268 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 269 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 270 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 271 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.2 CHINA
12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to drive growth
TABLE 272 CHINA: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 273 CHINA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 274 CHINA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 275 CHINA: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 276 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 277 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 278 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 279 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 280 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 281 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.3 INDIA
12.4.3.1 Increasing burden of diabetes and CVD to drive growth
TABLE 282 INDIA: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 283 INDIA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 284 INDIA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 285 INDIA: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 286 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 287 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 288 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 289 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 290 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 291 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.4 SOUTH KOREA
12.4.4.1 Regulatory approvals for autoinjectors to drive growth
TABLE 292 SOUTH KOREA: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 293 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 294 SOUTH KOREA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 295 SOUTH KOREA: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 296 SOUTH KOREA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 297 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 298 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 299 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 300 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 301 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.5 REST OF ASIA PACIFIC
TABLE 302 ROAPAC: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 303 ROAPAC: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 304 ROAPAC: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 305 ROAPAC: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 306 ROAPAC: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 307 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 308 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 309 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 310 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 311 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.4.6 ASIA PACIFIC: RECESSION IMPACT
12.5 LATIN AMERICA
12.5.1 RISING GERIATRIC POPULATION TO SUPPORT GROWTH
TABLE 312 LATIN AMERICA: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 313 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 314 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 315 LATIN AMERICA: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 316 LATIN AMERICA: MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 317 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 318 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 319 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 320 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 321 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 322 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 323 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.5.2 LATIN AMERICA: RECESSION IMPACT
12.6 MIDDLE EAST & AFRICA
12.6.1 FAVORABLE REFORMS IN AFRICA AND MIDDLE EASTERN COUNTRIES TO DRIVE GROWTH
TABLE 324 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 325 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 326 MIDDLE EAST & AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 327 MIDDLE EAST & AFRICA: MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 328 MIDDLE EAST & AFRICA: MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 329 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 330 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
TABLE 331 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
TABLE 332 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 333 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
TABLE 334 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
TABLE 335 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

13 COMPETITIVE LANDSCAPE (Page No. - 244)
13.1 INTRODUCTION
13.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 41 AUTOINJECTOR DEVICES AND FINISHED FORMULATIONS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
13.3 REVENUE SHARE ANALYSIS FOR AUTOINJECTORS MARKET
FIGURE 42 AUTOINJECTORS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
13.4 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET
FIGURE 43 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
13.5 MARKET SHARE ANALYSIS FOR AUTOINJECTORS MARKET
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET, 2022
TABLE 336 AUTOINJECTORS MARKET: DEGREE OF COMPETITION
13.6 MARKET SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET
FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET, 2022
TABLE 337 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION
13.7 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
FIGURE 46 AUTOINJECTORS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
13.8.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 338 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
13.8.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 339 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES
FIGURE 47 AUTOINJECTORS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
13.9.1 PROGRESSIVE COMPANIES
13.9.2 STARTING BLOCKS
13.9.3 RESPONSIVE COMPANIES
13.9.4 DYNAMIC COMPANIES
13.10 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 340 AUTOINJECTORS MARKET: LIST OF KEY STARTUP/SME PLAYERS
TABLE 341 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
13.11 COMPETITIVE SCENARIO AND TRENDS
13.11.1 PRODUCT LAUNCHES
TABLE 342 AUTOINJECTORS MARKET: PRODUCT LAUNCHES, JANUARY 2020-APRIL 2023
13.11.2 DEALS
TABLE 343 AUTOINJECTORS MARKET: DEALS, JANUARY 2020-APRIL 2023
13.11.3 OTHER DEVELOPMENTS
TABLE 344 AUTOINJECTORS MARKET: OTHER DEVELOPMENTS, JANUARY 2020-APRIL 2023
13.11.4 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
TABLE 345 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
13.11.5 DEVICES FOR LARGE-VOLUME FORMULATIONS
TABLE 346 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS
13.11.6 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
TABLE 347 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS
TABLE 348 FORMULATIONS AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS
13.11.7 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET

14 COMPANY PROFILES (Page No. - 264)
14.1 KEY PLAYERS: DEVICES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 BECTON, DICKINSON AND COMPANY (BD)
TABLE 349 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 350 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS
TABLE 351 BECTON, DICKINSON AND COMPANY: DEALS
TABLE 352 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS
14.1.2 YPSOMED HOLDING AG
TABLE 353 YPSOMED HOLDING AG: COMPANY OVERVIEW
FIGURE 49 YPSOMED HOLDING AG: COMPANY SNAPSHOT
TABLE 354 YPSOMED HOLDING AG: PRODUCT OFFERINGS
TABLE 355 YPSOMED HOLDING AG: PRODUCT LAUNCHES
TABLE 356 YPSOMED HOLDING AG: DEALS
14.1.3 SHL MEDICAL
TABLE 357 SHL MEDICAL: COMPANY OVERVIEW
TABLE 358 SHL MEDICAL: PRODUCT OFFERINGS
TABLE 359 SHL MEDICAL: DEALS
TABLE 360 SHL MEDICAL: OTHER DEVELOPMENTS
14.1.4 WEST PHARMACEUTICAL SERVICES, INC.
TABLE 361 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
FIGURE 50 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022)
TABLE 362 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT OFFERINGS
TABLE 363 WEST PHARMACEUTICAL SERVICES, INC.: OTHER DEVELOPMENTS
14.1.5 RECIPHARM AB
TABLE 364 RECIPHARM AB: COMPANY OVERVIEW
TABLE 365 RECIPHARM AB: PRODUCT OFFERINGS
TABLE 366 RECIPHARM AB: DEALS
14.1.6 HASELMEIER GMBH
TABLE 367 HASELMEIER GMBH: COMPANY OVERVIEW
TABLE 368 HASELMEIER GMBH: PRODUCT OFFERINGS
TABLE 369 HASELMEIER GMBH: DEALS
TABLE 370 HASELMEIER GMBH: PRODUCT LAUNCHES
14.1.7 OWEN MUMFORD LTD.
TABLE 371 OWEN MUMFORD LTD.: COMPANY OVERVIEW
TABLE 372 OWEN MUMFORD LTD.: PRODUCT OFFERINGS
TABLE 373 OWEN MUMFORD LTD.: PRODUCT LAUNCHES
TABLE 374 OWEN MUMFORD LTD.: DEALS
TABLE 375 OWEN MUMFORD LTD.: OTHER DEVELOPMENTS
14.1.8 GERRESHEIMER AG
TABLE 376 GERRESHEIMER AG: COMPANY OVERVIEW
FIGURE 51 GERRESHEIMER AG: COMPANY SNAPSHOT (2022)
TABLE 377 GERRESHEIMER AG: PRODUCT OFFERINGS
TABLE 378 GERRESHEIMER AG: DEALS
14.1.9 PHILLIPS-MEDISIZE, LLC
TABLE 379 PHILIPS-MEDISIZE, LLC: COMPANY OVERVIEW
TABLE 380 PHILIPS MEDISIZE, LLC: PRODUCT OFFERINGS
TABLE 381 PHILIPS MEDISIZE, LLC: PRODUCT LAUNCHES
TABLE 382 PHILIPS-MEDISIZE, LLC: OTHER DEVELOPMENTS
14.1.10 OVAL MEDICAL TECHNOLOGIES LTD. (PART OF SMC LTD.)
TABLE 383 OVAL MEDICAL TECHNOLOGIES LTD.: COMPANY OVERVIEW
TABLE 384 OVAL MEDICAL TECHNOLOGIES LTD.: PRODUCT OFFERINGS
14.1.11 KALEO, INC.
TABLE 385 KALEO, INC.: COMPANY OVERVIEW
TABLE 386 KALEO, INC.: PRODUCT OFFERINGS
14.1.12 SOLTEAM INCORPORATION CO., LTD.
TABLE 387 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW
TABLE 388 SOLTEAM INCORPORATION CO., LTD.: PRODUCT OFFERINGS
14.1.13 ELCAM DRUG DELIVERY DEVICES (E3D)
14.1.14 CROSSJECT
TABLE 391 CROSSJECT: COMPANY OVERVIEW
TABLE 392 CROSSJECT: PRODUCT OFFERINGS
14.1.15 JOHNSON MEDTECH, LLC. (PART OF JOHNSON ELECTRIC HOLDINGS LTD.)
TABLE 393 JOHNSON MEDTECH, LLC.: COMPANY OVERVIEW
TABLE 394 JOHNSON MEDTECH, LLC: PRODUCT OFFERINGS
14.1.16 ANTARES PHARMA, INC. (PART OF HALOZYME, INC.)
TABLE 395 ANTARES PHARMA, INC.: COMPANY OVERVIEW
FIGURE 52 ANTARES PHARMA, INC.: COMPANY SNAPSHOT
TABLE 396 ANTARES PHARMA, INC.: PRODUCT OFFERINGS
TABLE 397 ANTARES PHARMA, INC.: DEALS
14.1.17 JABIL, INC.
TABLE 398 JABIL, INC.: COMPANY OVERVIEW
TABLE 399 JABIL INC.: PRODUCT OFFERINGS
14.1.18 CONGRUENCE MEDICAL SOLUTIONS LLC
TABLE 400 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW
TABLE 401 CONGRUENCE MEDICAL SOLUTIONS LLC: PRODUCT OFFERINGS
14.2 KEY PLAYERS: FINISHED FORMULATIONS
14.2.1 ABBVIE INC.
TABLE 402 ABBVIE INC.: COMPANY OVERVIEW
FIGURE 53 ABBVIE INC.: COMPANY SNAPSHOT
TABLE 403 ABBVIE INC.: PRODUCT OFFERINGS
TABLE 404 ABBVIE INC.: PRODUCT LAUNCHES
TABLE 405 ABBVIE INC.: OTHER DEVELOPMENTS
14.2.2 AMGEN INC.
TABLE 406 AMGEN INC.: COMPANY OVERVIEW
FIGURE 54 AMGEN INC.: COMPANY SNAPSHOT
TABLE 407 AMGEN INC.: PRODUCT OFFERINGS
TABLE 408 AMGEN INC.: PRODUCT LAUNCHES
14.2.3 ELI LILLY AND COMPANY
TABLE 409 ELI LILY AND COMPANY: COMPANY OVERVIEW
FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 410 ELI LILY AND COMPANY: PRODUCT OFFERINGS
TABLE 411 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
14.2.4 NOVARTIS AG
TABLE 412 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT
TABLE 413 NOVARTIS AG: PRODUCT OFFERINGS
TABLE 414 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS
14.2.5 MERCK KGAA
TABLE 415 MERCK KGAA: COMPANY OVERVIEW
FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT
TABLE 416 MERCK KGAA: PRODUCT OFFERINGS
14.2.6 VIATRIS INC. (FORMERLY MYLAN INC.)
TABLE 417 VIATRIS INC.: COMPANY OVERVIEW
FIGURE 58 VIATRIS INC.: COMPANY SNAPSHOT
TABLE 418 VIATRIS INC.: PRODUCT OFFERINGS
14.2.7 BIOGEN
TABLE 419 BIOGEN: COMPANY OVERVIEW
FIGURE 59 BIOGEN: COMPANY SNAPSHOT
TABLE 420 BIOGEN: PRODUCT OFFERINGS
TABLE 421 BIOGEN: OTHER DEVELOPMENTS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX (Page No. - 320)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS